UF Health Pathology Laboratories’ Tumor Mutation Analysis by Next-Generation Sequencing (NGS) now evaluates 33 genes. (references UF Health Pathology Laboratories Medical Director Robert W. Allan, M.D., and Molecular Pathology Director Petr Starostik, M.D.)

To: All involved in patient care


Petr Starostik, MD
Molecular Pathology Director
UF Health Pathology Laboratories

Robert W. Allan, MD
Medical Director
UF Health Pathology Laboratories

Re: Expanded Tumor Mutation Analysis by Next-Generation Sequencing (NGS) (version 2.0) at UF Health Pathology Laboratories

Starting July 13, 2015, University of Florida Health Pathology Laboratories is pleased to offer an expanded version of its clinical next-generation sequencing mutation panel, which covers mutation hotspots in 33 genes. This enhanced-coverage panel replaces the former version of the assay (Solid Tumor Mutation Analysis by Next-Generation Sequencing (NGS) (BRAF, EGFR, ERBB2, KRAS, NRAS, PIK3CA)), which only covered six genes and was focused only on lung and colorectal cancers.


There are no changes in ordering this test panel in the Epic EMR. The preferred specimen for evaluation is still formalin-fixed, paraffin-embedded tissue blocks; however, fresh tissue or cell suspensions are also acceptable. Turnaround time is seven to 10 days from the moment samples are received at the laboratory. Results are posted in Epic.

Mutation hotspots in the following genes are now evaluated with this panel:

  • ABL1
  • AKT1
  • ALK
  • BRAF
  • CTNNB1
  • EGFR
  • ERBB2/HER2
  • EZH2
  • FBXW7
  • FGFR1
  • FGFR2
  • FLT3
  • GNA11
  • GNAQ
  • HRAS
  • IDH1
  • IDH2
  • JAK2
  • KIT
  • KRAS
  • MET
  • MPL
  • NOTCH1
  • NPM1
  • NRAS
  • PIK3CA
  • PTEN
  • PTPN11
  • RET
  • SMAD4
  • SMO
  • TP53

If you have any questions on this test, call UF Health Pathology Laboratories’ Client Services Department at 352.265.9900.